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ABSTRACT 
This case report describes the improvement obtained by using tranylcypromine in a patient 
of severe treatment resistant depression. The adverse effects faced and steps taken to overcome 
them have also been discussed. 
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The first MAOI, iproniazid, was identified 
as an antidepressant in 1952 (Himmelhoch, 
1995). Other types of MAOI were gradually 
developed and their use as antidepressants 
continued till 1962. Around that time 
concern regarding hypertensive crises and 
hepatotoxicity increased. A case report of death 
on consumption of cheese was reported and over 
a few years MAOI went out of use. It's only in 
the mid 1980's that MAOI again began to be used 
when it was found that fears regarding their side 
effects were not as serious as to limit their use 
completely for valid indications. Now MAOI as 
antidepressants are well accepted and described 
in pharmacological texts (Hollister, 1995). 
Pare et al. (1962) thought patients 
responding to MAOI had a different genetic 
specification in comparison to those responding 
to imipramine. Quitkin et al. (1979) has shown 
the use of phenelzine in atypical depression and 
tranylcypromine was also seen to show promise. 
Atypical depression especially those with anergia 
and vegetative symptoms have been found 
to respond better to tranylcypromine 
(Himmelhoch, 1995). Tranylcypromine has also 
been shown to be useful in anergic bipolar 
depression (Himmelhoch et al.,1991) Murphy et 
al. (1984) has reviewed its use even in 
endogenous depression. 
Use of MAOI in treatment resistant 
depression has been outlined by Trivedi et al. 
(1993), Amsterdam & Hornig-Rohan (1996), 
Homig-Rohan et al. (1996) and Sharan & Saxena 
(1998). 
However in India, there has been no 
reported use of MAOI in psychiatric literature in 
the recent years. 
The present case is being reported to 
describe our experience with tranylcypromine in 
a patient with resistant depression. 
CASE REPORT 
Mr. P. S., a 42 year old, married, sanitary 
inspector presented .with a 5 year continuous 
illness of insidious onset and fluctuating course. 
The initial symptoms were of anxiety, giddiness 
and sadness. He was investigated for 
cardiological problem by a specialist and no 
anomaly was evident on ECG, cardiac 
angiogram and TMT. Gradually over 1 year the 
symptoms worsened. He preferred to remain 
alone and didn't feel like interacting with other 
family members or guests. He also used to 
express sadness of mood and irritability. At times 
he suspected that someone had done some 
sorcery (jadu tona) on him which had caused 
the illness. The symptoms waxed and waned but 
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showed no particular exacerbating or remitting 
factor. Within 2 years of onset of illness he 
started to have, reduced interest in work and 
lethargy. He stopped going to his job. He did not 
find any pleasure in any activity and had 
pessimism, death wishes, reduced personal 
care, reduced appetite, weight loss and inability 
to sleep throughout the night. He had no history 
of hearing voices, thought insertion, thought 
withdrawal, thought broadcast, suspiciousness 
of being followed or poisoned or selfmuttering. 
He had never shown any features of increased 
happiness or elation or grandiosity. No history 
suggestive of altered conciousness, loss of 
memory or intellectual decline was present. 
Past history showed alcohol use which had 
stopped since his illness started however no 
features suggestive of dependence were 
present. No other history suggestive of 
psychiatric illness was present. Family history 
did not reveal any psychiatric illness. There were 
no history of continuing stress in the personal 
life and premorbidly he seemed well adjusted. 
Till his first admission at our centre he had 
been treated with various combinations of 
medicines which included lorazepam (upto 2 mg/ 
day), alprazolam (upto 1.5 mg/day), diazepam 
(upto 35 mg/day), propranol (upto 40 mg/day), 
imipramine (upto 150 mg/day), fluoxetine (upto 
20 mg/day). Medications were never given for 
adequate time intervals or in adequate doses. 
At the time of admission his physical 
examination and preliminary investigations 
including thyroid function showed no abnormality. 
Mental status examination showed an average 
built man with normal psychomotor activity but 
with depressed affect, ideas of persecution, 
hopelessness, worthlessness, death wishes. No 
perceptual abnormality was detected. Other 
cognitive functions were normal and insight was 
present. 
A diagnosis of severe depressive episode 
without psychotic features as per ICD-10 was 
made and the patient was initially started on 
nortryptiline upto 200 mg/day along with 
benzodiazepine. Lithium augmentation upto 900 
mg/day was started after 3 weeks when no 
improvement occurred. Even after 6 weeks of 
nortryptiline of which 3 weeks were with lithium 
augmentation the patient showed no 
improvement. Modified ECT were then started 
and 2 ECTs per week were given for 5 weeks and 
then stopped when the patient started to show 
mild memory impairment. By now the 
improvement shown by the patient was only 30%. 
At that point lithium and nortryptiline was also 
stopped and imipramine upto 225 mg/day was 
given for 4 weeks. Beyond that the patient 
showed postural hypotension. Fluoxetine 20 mg/ 
day was added after that and at discharge, after 
a total stay of three and half months, he was on 
imipramine (200 mg/day), fluoxetine (20 mg/day) 
and alprazolam (1 mg/day). This continued for 
6 weeks with no further improvement above the 
30% improvement shown before. On follow-up 
he was taken off all these medications and put 
on buspirone (30mg/day) chlordiazepoxide (60 
mg/day) and flurazepam (15mg/day). The patient 
took these medications for 3 weeks, did not find 
any improvement, and dropped out of follow-
up. His condition continued to worsen till he again 
followed up with us after 7 months during which 
he had been often taking alprazolam upto 1 mg 
for sedation. 
The patient was admitted for a second 
time as during the past 7 months there had been 
3 suicidal attempts. Mental status examination 
showed a depressed affect, suicidal ideas, 
pessimism, ideas of reference and persecution. 
No perceptual abnormality was present. Other 
cognitive functions were intact and insight was 
present. Hamilton anxiety and depression scores 
showed values of 34 and 33 respectively. 
A decision to start a MAOI was taken 
seeing his previous poor response to other forms 
of treatment. A two week washout period was 
given prior to starting tranylcypromine. 
Tranylcypromine was initially started in a 10 mg 
OD dose with twice daily BP monitoring to look 
for postural hypotension. Diet monitoring was 
done. The dose was gradually increased by 10 
mg every 2 - 3 days till 40 mg/day (10 mg/QID) 
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was reached. At that point the patients, 
Hamilton Anxiety Score (HAS) was 35 and 
Hamilton Depression Score (HDS) was 27. Within 
2 weeks the scores were HAS-23, HDS-19. The 
patient also showed both objective and 
subjective improvement in sadness, pessimism, 
suicidal thoughts, ideas of reference and 
persecution. Weekly assessment of Hamilton 
Anxiety and Depression scores showed decrease 
of values and by 6 weeks of onset of 
tranylcypromine treatment the values had 
dropped to 16 and 12 respectively. The patient's 
sadness was no more sustained. Suicidal idea-, 
ideas of reference and persecution, pessimism, 
had disappeared. Mild degree of anxiety and 
sadness remained along with mild lethargy and 
insomnia. Giddiness and anxiety was also ill 
sustained. The patient had started socializing 
with other patients and relatives and the patient 
was sent to work from the ward. The patient 
continued this arrangement for 1 week with 
minor physical tiredness and seemed happy at 
being able to resume his job after 6 years of 
leave. The patient was discharged from the ward 
and during follow-ups he continued to perform 
satisfactorily. At 6 month follow up the patient 
was working, had occasional sadness and 
anxiety and was pleased with his condition. 
During the stay in the hospital the 
patient had shown the following side-effects of 
MAOI. 1) Dizziness due to postural hypotension 
for which he was told to take increased amounts 
of fluid 'with added salt. At least 3 litres of water 
with 1 packet oral rehydration solution with added 
salt was used by the patient daily on which his 
postural drop remained within control, though 
dizzinessto a mild degree remained. 2) Insomnia 
was treated initially with trazodone upto 
100 mg/day but when postural hypotension 
worsened he was shifted to flurazepam upto 45 
mg at night with which sleep improved. 
3) Idiosyncratic hypertension upto 190 mg Hg 
systolic and 110 mg Hg diastolic occured on two 
occassions but these could be easily managed 
with sublingual nifedipine upto 10 mg period. 
DISCUSSION 
Ayd (1995) has defined treatment 
resistant depression (TRD) as unremitting 
depression despite treatment with at least two 
different antidepressants or an antidepressant 
and a course of electroconvulsive therapy. 
TRD has also been defined by others and 
Sharan et al. (1998) reviewed the concept of 
TRD and defined it as a continuum in which 
the degree of treatment resistance is 
ascertained by taking into account the number 
and quality of failed antidepressant trials. 
In our patient we had failed with two 
different types of tricyclics upto the maximum 
tolerated dosage and for adequate duration. 
Lithium augmentation, electroconvulsive therapy 
and fluoxetine had also failed and so a diagnosis 
of treatment resistant depression was made and 
tie decision to start MAOI was taken. 
Our patient was taking alprazolam 
tablets as self medication for sedation, off and 
on, prior to his second admission and so a 
washout period was given. Tranylcypromine 
(Parnate), instead of phenelzine was chosen as 
it was available locally. The dose of 
tranylcypromine is generally between 20-60 mg/ 
day but a large number of patients require higher 
doses (Himmelhoch,1995). The patient was then 
started on tranylcypromine 10 mg/day and the 
dose was titrated while side effects were noted 
and for which a 5 week inpatient.stay was 
required. He could tolerate upto 40 mg/day when 
significant postural hypotension occured. 
Postural hypotension and insomnia are 
notable side effects of MAOI and 
tranylcypromine has been shown to have 
idiosyncratic pressor reactions unrelated to food 
as had been seen in this patient. Different 
hypothesis have been forwarded by Keck et al., 
(1991). to explain this phenomenon but no 
definite reason has been found. A list of all food 
items to be avoided by the patient were given to 
him on the basis of directions given by 
Himmelhoch (1995) and Murphy et al. (1984). 
The major items among them, that are generally 
consumed in India are cottage cheese (paneer), 
chocolates, alcohol (in moderation), soyasauce, 
curd and some fruits. None of the above have 
high tyramine content and so have less chance 
of causing any hypertensive crises. Among 
alcoholic drinks only red wine is high in tyramine 
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content. 
We could achieve significant 
improvement in the patients symptoms and 
functioning capability within 6 weeks. Table 1 
has outlined the change in score in the Hamilton 
Depression Scale (Marder, 1995) and Hamilton 
Anxiety Scale (Marder, 1995) over the 6 week 
period of inpatient stay and it indicates the utility 
of tranylcypromine in our patient who suffered 
from TRD. 
In India, the use of MAOI for depression, 
has not been forthcoming probably due to its poor 
availability, apprehension regarding its side effects, 
precautions to be taken and requirement of a long 
inpatient stay for titration of doses. But this case 
shows the utility of MAOI in the treatment of TRD. 
In conclusion, we suggest that MAOI can 
be used in clinical practice as a possible 
treatment for TRD, while observing all necessary 
precaution recommended in the literature. 
TABLE 1 
SCORE ON HAMILTON ANXIETY SCALE (HAS) AND 
HAMILTON DEPRESSION SCALE (HOS) 
Baseline 
The point when 
tranylcypromine 
40 mg/day was 
reached 
2 week after max. 
tolerated dose was 
reached 
3 week after max. 
tolerated dose was 
reached 
At discharge 
Weeks 
0 
2 
4 
5 
6 
HAS 
max. 
score(56) 
34 
35 
23 
19 
16 
HDS 
max. 
score(64) 
33 
27 
19 
14 
12 
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